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Introduction
The great majority of patients with Hodgkin lymphoma 
(HL) can be cured with chemotherapy or a combination 
of chemo and radiotherapy. There is, however, a propor-
tion of patients, in particular those presenting with advanced 
stage disease, who will succumb to the disease [1]. Balancing 
the aggressiveness of treatment between disease control 
and risk of short- and long- term toxicity remains a chal-
lenge for treatment decisions in HL [2]. Aggressive treat-
ment of advanced stage disease using the BEACOPP regimen 
has certainly improved disease- free survival, at the cost of 
infertility and risk of secondary organ damage and neo-
plasias [3–7]. Classical clinical and laboratory risk factors 
at diagnosis appear to be of little help for treatment deci-
sions in patients with advanced HL [8, 9].
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Abstract
Early response evaluation with [18F]fluordeoxyglucose (FDG) positron emission 
tomography after 2 cycles of chemotherapy (interim PET) has been indicated 
as the strongest predictor for outcome in classical Hodgkin lymphoma (HL). 
We studied the prognostic role of the number of tumor- infiltrating CD68+ cells 
and of the plasma levels of TARC (thymus and activation- regulated chemokine) 
in the context of interim PET in 102 patients with classical HL treated with 
Adriamycin, Bleomycin, Vinblastine, Dacarbazine (ABVD). After 2 ABVD cycles, 
interim PET according to Deauville criteria was negative (score 0–3) in 85 
patients and positive (score 4–5) in 15 patients (2 patients technically not evalu-
able). TARC levels were elevated in 89% of patients at diagnosis, and decreased 
after 2 cycles in 82% of patients. Persistently elevated TARC levels in 18% of 
patients were significantly associated with a positive PET result (P = 0.007). 
Strong predictors for progression- free survival (PFS) were a negative interim 
PET (85% vs. 28%, P < 0.0001) and CD68+ cell counts <5% (89% vs. 67%, 
P = 0.006), while TARC levels at diagnosis and at interim evaluation had no 
prognostic role. In multivariate analysis, interim PET, CD68+ cell counts and 
presence of B- symptoms were independently associated with PFS. We conclude 
that although TARC levels are a biomarker for early response evaluation, they 
cannot substitute for interim PET as outcome predictor in HL. The evaluation 
of CD68 counts and B- symptoms at diagnosis may help to identify low- risk 
patients regardless positive interim PET.
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In 2006, Gallamini et al. and Hutchings et al. reported 
that PET examination with [18F]fluorodeoxyglucose (FDG) 
after 2 cycles of standard chemotherapy, later on termed 
“interim- positron emission tomography (PET)”, discrimi-
nates PET- negative patients with a very high probability 
of disease control with the standard chemotherapy regimen 
Adriamycin, Bleomycin, Vinblastine, Dacarbazine (ABVD), 
from PET- positive patients where standard therapy is most 
likely to fail [10, 11]. These data were confirmed by several 
studies on patient groups with limited or advanced stage 
disease treated with ABVD, while the prognostic value of 
interim PET for patients treated with BEACOPP is not 
well established [12–15]. During a consensus meeting at 
Deauville in France, criteria have been standardized to 
evaluate interim PET, by using a 5- point scale [16]. The 
5- point scale uses uptakes by the mediastinal blood flow 
and the liver to quantify residual uptake in a visual evalu-
ation. The Deauville criteria are now widely considered 
as the most appropriate evaluation method for interim 
PET [17]. A PET- guided treatment approach allows the 
early identification of interim PET- positive patients, with 
insufficient response to standard treatment, as candidates 
for intensive, although potentially more toxic, treatments 
[18]. This approach is currently evaluated in prospective 
studies. A drawback of the PET- guided approach is that 
patients with poor prognostic features are only identified 
after 2 months of treatment, significantly delaying intensive 
treatment choices. In addition, there is a small, but con-
sistent proportion of interim PET- negative patients who 
will progress or relapse, with a progression- free survival 
(PFS) around 80–85% as indicated by recent preliminary 
data [19]. This leaves room for other potential prognos-
ticators in addition to interim PET. For patients with 
refractory/relapsed HL, Moskowitz et al. showed that in-
volvement of extranodal sites and a positive PET result 
pre- high- dose therapy were independent risk factors [20].
A particular feature of HL is that the neoplastic cells 
vitally depend on the supporting microenvironment. The 
cellular composition of the microenvironment impacts 
prognosis in HL. In 2010, a gene expression study by 
Steidl et al. pointed to the prominent role of tumor- 
infiltrating macrophages in HL lymphnode biopsies [21]. 
Over 5% tumor- infiltrating macrophages identified by 
immunohistochemical staining for the CD68 antigen pick 
out patients at higher risk for PFS. The number of CD68+ 
macrophages outperformed the international prognostic 
score (IPS) in multivariate analysis. These data have been 
confirmed by several groups, including ours [22–29]. 
CD68+ cell counts appear as the most reproducible and 
simple prognostic marker reflecting tumor biology and is 
currently available, using routine diagnostic methods.
Another common feature of the tumor microenviron-
ment in HL is the overrepresentation of tolerogenic T- cell 
populations, that include T helper 2 (TH2) cells and 
regulatory T cells (Treg). These cells create a favorable 
immunological environment for the survival and prolifera-
tion of HRS cells. The chemokine thymus and activation- 
regulated chemokine (TARC), also termed CCL17, engages 
the chemokine receptor CCR4 expressed on regulatory T 
and TH2 cells, recruiting these cells into HL lesions. TARC 
is highly expressed by HRS cells, secreted into the serum, 
and can be detected at high levels at HL diagnosis [30–32]. 
Recent data suggest that early changes in TARC levels 
during chemotherapy may be a biomarker for response 
evaluation [33, 34].
We studied whether microenvironment CD68+ cell 
counts and TARC levels at HL diagnosis and following 
2 cycles of ABVD add prognostic information to interim 
PET.
Materials and Methods
Patient characteristics
Our analysis included 102 patients (median age 38 years, 
range 15–74 years; 47 females and 55 males), diagnosed 
with classical HL and treated between February 2007 and 
January 2014 at the Department of Hematology of the 
Catholic University in Rome. Patient characteristics, in-
cluding the IPS score [35] are detailed in Table 1. All 
patients received chemotherapy according to the ABVD 
protocol. Patients with limited stage disease received 3 
or 4 ABVD cycles, according to the presence of other 
risk factors as defined by the EORTC [36], followed by 
involved- field radiotherapy. Patients with advanced stage 
disease received 6 cycles of ABVD. Only 3 patients with 
advanced stage disease, with a positive interim PET result 
(score 4–5 according to Deauville criteria) after 2 cycles 
of ABVD, were switched to BEACOPP (6 cycles of dose- 
escalated BEACOPP). Two of them did not achieve meta-
bolic remission after the second- line treatment. 
Radiotherapy was included for consolidation in patients 
with a limited- stage disease and initial bulky disease. 
Informed consent was obtained from patients according 
to institutional guidelines. The study has been approved 
by the Institutional review board.
Immunohistochemical analysis
Immunohistochemical analysis for CD68 was performed 
on 3 μm tissue slides, using the antihuman mouse mono-
clonal antibody CD68 (1:100, clone PGM- 1; Dako, High 
Glostrup, Denmark) after proteolytic treatment (pronase 
0.05% in tris buffer pH 7.6) for 10 min at room tem-
perature. Immunodetection was performed using an avi-
din–biotin–peroxidase complex solution (ScyTek, Logan, 
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UT), 3,39- diaminobenzidine as the chromogen, and Mayer 
hematoxylin as the counterstain. We used the immuno-
histochemical score proposed by Steidl et al. with a cut- off 
at 5% CD68- positive cells [21].
ELISA for plasma TARC levels
Plasma samples were collected prior to treatment start and 
at interim PET, and stored at −70°C. TARC levels were 
determined using a sandwich enzyme- linked immunoassay, 
according to the manufacturer’s instructions (Human CCL- 
17/TARC DuoSet, R&D Systems, Inc., Minneapolis, MN). 
A group of 63 healthy individuals (29 males, 34 females; 
median age 33 years) was used as control group.
Interim PET
PET- CT studies were performed using an integrated 
PET- CT device (GEMINI GXL distributed by Philips 
Medical System or BIOGRAPH distributed by Siemens. 
PET- CT images were evaluated by two independent nuclear 
medicine physicians, using a dedicated fusion and display 
software (SYNTEGRA by Philips, Milan, Italy or SYNGO.
VIA by Siemens, Milan, Italy).
Interim PET was performed after the second ABVD 
course, few days before the third course. The criteria for 
PET- 2 interpretation were based on visual assessment of 
FDG uptake, and scored for intensity of FDG uptake ac-
cording to the Deauville 5- point scoring system [16, 17]. 
Interim PET scans with a score of 4 that equals a FDG 
uptake that moderately exceeds the FDG uptake in the 
liver, and 5 (markedly increased uptake > liver and/or new 
lesions related to lymphoma) were considered positive.
Statistical analysis
Fisher’s exact test was used to examine for differences in 
patient characteristics according to interim PET and the 
CD68+ cell count. Wilcoxon signed rank test was used 
for two- sample comparisons of TARC plasma levels, as 
between patient and control groups, or according to 
 dichotomized patient characteristics. The primary survival 
end point was PFS, with progression during treatment, 
lack of complete remission at the end of first- line treat-
ment, relapse, and death from any cause counted as adverse 
events. A positive interim PET result in the absence of 
progression that lead to change in therapy from ABVD 
to BEACOPP in 3 patients was not counted as event. 
Survival curves were estimated using the Kaplan–Meier 
product limit method. Log- rank tests were used to analyze 
for differences in PFS. Hazard ratios and 95% confidence 
intervals were adjusted for multiple prognostic factors 
using the Cox proportional hazards model. All parameters 
that resulted significant (P < 0.05) in the univariate analysis 
were included into the multivariate analysis. These factors 
were: interim PET result, stage of disease, presence of 
B- symptoms, IPS score, and CD68 count. In order to 
optimize the prognostic model, we performed a stepwise 
model selection using the Akaike information criterion 
(AIC). Computations were performed using the Stata 10.0 
software (Stata Corp., College Station, TX).
Results
Interim PET
Interim PET- CT scans following 2 ABVD cycles were 
scored according to the Deauville scoring system in 102 
patients with classical HL. In 2 patients, significant FDG 
accumulation within brown fat tissue did not allow to 
discriminate for metabolic activity in sites of previous 
disease. The interim PET scan was scored negative 
Table 1. Patient characteristics and interim PET.
Patient 
characteristics Patients
Interim PET
P1Negative Positive
Number 102 85 15
Age
 Median, 
range (year)
38 (15–74) 38 (15–74) 44 (20–72)
 >45 years 29 (29%) 23 (27%) 6 (40%) 0.4
Gender
 Male 55 (54%) 44 (52%) 11 (73%) 0.2
Histologic subtype
 NS 86 (84%) 71 (84%) 13 (86%) 1.0
 NS 1 45 (44%) 38 (45%) 7 (47%)
 NS 2 27 (26%) 21 (25%) 4 (27%)
 MC 4 (4%) 3 (4%) 1 (7%)
 LR 2 (2%) 2 (2%) 0 (0%)
 NOS 10 (10%) 9 (10%) 1 (7%)
Stage
 Advanced 
(IIB- /IV)
49 (48%) 36 (42%) 13 (87%) 0.002
B- symptoms
 Yes 38 (37%) 28 (33%) 10 (67%) 0.02
Bulk >5 cm
 Yes 54 (53%) 44 (52%) 9 (60%) 0.6
IPS score
 ≥2 25 (25%) 15 (18%) 10 (67%) 0.001
NS, nodular sclerosis; NS1, nodular sclerosis type 1 according to BNLI 
criteria; NS2, nodular sclerosis type 2 according to BNLI criteria; MC, 
mixed  cellularity; LR, lymphocyte- rich; NOS: not otherwise specified; IPS, 
international prognostic score.1
P- value of Fisher’s exact test. Wilcoxon ranked sum test was used for com-
parison of median age. Two patients were excluded from the analysis, as 
interim PET was scored not evaluable due to unspecific FDG accumulation.
Significant P-values are shown in bold.
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(Deauville score 0–3), in 85 patients (83%), while it was 
positive in 15 patients (15%). Looking at patients’ char-
acteristics, there was a significant association between 
interim PET- positivity, advanced stage of disease 
(P = 0.002), presence of B- symptoms at diagnosis 
(P = 0.02) and an IPS score >2 (P = 0.001) (Table 1).
TARC levels at diagnosis and interim PET
TARC levels were determined at diagnosis in 80 patients, 
and were significantly higher than those of controls 
(P > 0.001) (Fig. 1). TARC levels were above the normal 
range (upper limit 162 U/mL) at diagnosis in 89% (71/80) 
of patients with cHL. Significantly higher TARC levels 
were observed in patients younger than 45 years (P = 0.02), 
and patients with bulky disease (P = 0.02) (Table 2). 
Plasma was available at the time of interim PET in 65 
patients. TARC levels decreased at interim PET in 57 
patients, but persisted elevated (>162 U/mL) in 12 patients 
(18%) (Fig. 2). Persistently elevated TARC levels were 
significantly associated with a positive PET result 
(P = 0.007) (Fig. 2).
Association of the number of CD68+ 
macrophages with patient characteristics 
and interim PET results
Tumor biopsies of 79 patients at the time of HL diagnosis 
were stained for the CD68 antigen and scored using the 
immunohistochemical system proposed by Steidl et al. 
[21]. Over 5% CD68 positive cells were counted in 39/79 
(49%) patients. CD68+ cell counts >5% were frequent 
in patients aged over 45 years (17/22, 77%), when com-
pared to younger patients (24/59, 41%) (P = 0.005). There 
were no other associations between CD68+ cell count 
and patient characteristics as listed in Table 1.
We observed a direct correlation between interim PET 
score and CD68 cell counts in the tumor biopsy. When 
grouping patients according to the consensus cut for PET- 
positivity, which is score 4 [16], the association between 
a positive interim PET and higher CD68 counts was not 
significant (8/39, 21% vs. 4/40, 10%; P = 0.2). On the 
other hand, patients with interim PET score 1 or 2 ac-
cording to the Deauville system frequently had less than 
5% CD68+ counts, while patients scored 3–5 had signifi-
cantly higher CD68+ cell counts at diagnosis (P < 0.05) 
(Table 3).
Associations of CD68+ cell count and interim 
PET with outcome
At a median follow- up of 32 months (range 4–88 months), 
23 of 102 patients had disease progression, which trans-
lated into a 77% probability of PFS (95% CI, 67–84%). 
The univariate analysis showed that positive interim PET 
was associated with significantly worse PFS (P < 0.0001) 
(Fig. 3A), as was the number of CD68+ macrophages 
(P = 0.006) (Fig. 3B), advanced stage of disease (P = 0.008), 
presence of B- symptoms (P = 0.0002, Fig. 3C) and IPS 
Figure 1. Thymus and activation- regulated chemokine (TARC) Plasma 
levels are increased in Hodgkin lymphoma (HL) patients at diagnosis 
than in controls. TARC levels were significantly higher in HL patients 
(n = 80, median 162 U/mL) when compared to controls (n = 63, median 
64 U/mL) (P < 0.001). The upper border of the box indicates the 75th 
percentile, while the lower border indicates the 25th percentile, and the 
horizontal line in the box the median. The vertical lines are the whiskers 
indicating the maximum and minimum values. TARC levels in controls 
were used to define the upper normal value (dashed line, 162 U/mL).
Table 2. Thymus and activation- regulated chemokine (TARC) levels ac-
cording to patient characteristics.
Parameter Variable
Cases 
(n = 80)
TARC (U/mL) 
median P1
Age <45 years 58 2613 0.02
>45 years 22 811
Gender Female 40 2571 0.07
Male 40 949
Histologic subtype NS 70 1885 0.1
Others 10 661
Stage Limited 42 1100 0.08
Advanced 38 2612
B- symptoms No 55 1182 0.2
Yes 25 2059
Bulk >5 cm No 31 942 0.02
Yes 47 3829
IPS IPS 0–2 61 1482 0.7
IPS 3–7 19 2554
CD68+ <5% 30 3206 0.1
>5% 33 924
1P- value of Wilcoxon ranked sum test that was used for comparison of 
TARC levels according to patient characteristics.
Significant P-values are shown in bold.
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score >2 (P = 0.009, data not shown). TARC levels at 
diagnosis and at interim PET had no prognostic signifi-
cance (Fig. 3D and E). We also analyzed the prognostic 
relevance of interim TARC levels in addition to interim 
PET results. Interim TARC levels did not add any prog-
nostic information to interim PET (P = 0.4 for interim 
PET negative patients, P = 0.5 for interim PET positive 
patients).
The multivariate Cox proportional hazard regression 
analysis showed that interim PET, number of CD68+ cells 
and the presence of B- symptoms were independent prog-
nostic factors (P = 0.001, P = 0.01, and P = 0.04, re-
spectively), while the IPS score and stage of disease did 
not play a significant role (Table 4). A stepwise model 
selection using the AIC confirmed a multivariate model 
including the interim PET, number of CD68+ cells, and 
presence of B- symptoms.
Integrating the three significant parameters, we were 
able to identify patient groups characterized by significantly 
different prognosis. Patients (n = 30) with <5% CD68+ 
cell counts, without B- symptoms had a 92% (95% CI: 
72–98%) probability of PFS, independent from interim 
PET scan result (Fig. 4A). Patients with both B- symptoms 
and CD68+ cell counts >5% (n = 17) had a poor prog-
nosis (PFS of 45%; 95% CI: 20–66%). In this group, a 
negative interim PET identified a still favorable prognostic 
group, compared to patients with a positive PET (PFS: 
72% vs. 0% for patients with a positive interim PET, 
P = 0.003) (Fig. 4C). Patients with either B- symptoms 
or CD68+ cell counts >5% (n = 31) and a negative in-
terim PET still had a trend for better outcome (85% vs. 
33% at 32 months, P = 0.06) (Fig. 4B).
Discussion
We report that the number of CD68+ tumor- infiltrating 
macrophages and presence of B- symptoms are prognostic 
markers in ABVD- treated HL also in the era of interim 
PET, while changes in TARC levels do not add prog-
nostic information. More importantly, this is the first 
study showing that the integration of interim [18F]- FDG- 
PET/CT scan results after 2 chemotherapy cycles with 
presence of B- symptoms and CD68+ cell counts at di-
agnosis, improves risk- stratification of patients with HL. 
This additional information may help to identify a group 
of low- risk patients for whom interim PET is not pre-
dictive, and a high- risk patients group who are still at 
risk also when PET is negative. In our study, the interim 
PET evaluation was performed according to the recom-
mended 5- point Deauville scale [17]. PET results in our 
patients are in line with other recent reports on 84% 
PFS of interim PET- negative patients [19]. However, 
these figures are lower than initial studies, who reported 
more than 90% PFS in interim PET- negative patients 
[10, 11, 19].
We found that TARC plasma levels were elevated at di-
agnosis in the vast majority of patients with classical HL, 
and turned to normal following 2 cycles of ABVD. Persistently 
elevated TARC levels were associated with a higher risk of 
a positive interim PET. This is in line with two recent 
Figure 2. Elevated Plasma levels of thymus and activation- regulated chemokine (TARC) at diagnosis predicted interim positron emission tomography 
(PET) results. TARC levels were elevated at interim PET in only 6 of 51 (12%) patients with a negative interim PET (A), while they persisted elevated in 
6 of 12 (50%) patients with a positive interim PET (B, P = 0.007). The dashed line indicates the upper normal value.
Table 3. CD68+ cell count and interim positron emission tomography 
(PET).
Interim PET (Deauville 
score)
CD68
Total no. of 
patients<5% >5%
1 18 15 33
2 17 9 26
3 1 7 8
4 4 7 11
5 0 1 1
Total 40 39 79
P < 0.05, Fisher’s exact test. Patients with CD68 counts <5% had lower 
Deauville scores at interim PET when compared to patients with CD68 
counts >5%.
Significant P-values are shown in bold.
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studies suggesting that early changes of TARC may be a 
useful blood biomarker [33, 34]. However, in our study 
absolute TARC levels or their changes did not add prog-
nostic information to interim PET. Studied with larger patient 
numbers and events are required to address this issue.
Macrophage count was higher than 5% in about half 
of the patients, and was associated to patients’ age over 
45 years. This is in line with our previous observation, 
indicating that the number of CD68+ cells is higher in 
EBV- associated HL that is typically more frequent in older 
Figure 3. Progression- free Survival according to interim [18F]fluordeoxyglucose (FDG)- positron emission tomography (PET)/CT scan, CD68+ cell counts 
and thymus and activation- regulated chemokine (TARC) levels at diagnosis and at interim PET. Patients with an interim PET score of 1–3 were 
considered PET- negative (n = 85), and patients with a score of 4–5 were scored PET- positive (n = 15). After a median observation time of 32 months, 
the probability of progression- free survival (PFS) was 85% (95% CI: 75–91%) for PET- negative patients, while it was only 28% (95% CI: 8–53%) for 
PET- positive patients. The difference was highly statistically significant (P < 0.0001). (A) Patients with CD68+ cell counts <5% (n = 40) had a 
significantly higher probability of PFS at 32 months (89%, 95% CI: 72–96%), than patients with CD68+ cell count >5% (n = 39) (67%, 95% CI: 
50–79%; P = 0.006). (B) The PFS probability was similar for patients with TARC levels below or over >1000 U/mL at initial diagnosis (n = 32 and 
n = 48, respectively) (C) Petients with increased TARC levels (>162 U/mL, n = 12) at interim PET had a PFS (PFS: 67%, 95% CI: 34–86%), similar to 
patients with TARC levels <162 U/mL (n = 53, PFS: 80%, 95% CI: 66–89%, P = 0.3). (D) Patients with B- symptoms (n = 38) had a significant inferior 
probability of PFS (57%, 95% CI: 39–72%), when compared to patients without B- symptoms (n = 64) (88%, 95% CI:77–94%) (P = 0.002).
(A)
(C)
(B)
(D
(E)
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patients [22]. Patients with >5% CD68+ cell counts were 
likely to have a higher (≥3) Deauville score at interim 
PET. A Deauville score of 3 defines a residual FDG uptake 
higher than the mediastinal blood flow, but not exceeding 
activity in the liver. Potential associations between the 
CD68 count in the microenvironment and PET results 
in HL have been recently addressed, with conflicting re-
sults. Touati et al. [28], reported that the frequency of 
CD68+ cells correlates to interim- PET results. In contrast, 
Agur et al. [29] reported that CD68 counts correlate to 
the initial tumor mass and residual tumor size, but not 
to interim PET result and PFS. We think that homogenous 
treatment, standardized scoring of interim PET according 
to Deauville criteria, and CD68 evaluation by an expert 
hematopathologist, eliminating inter- observer variability 
are key issues of quality in our study.
The direct correlation between number of CD68+ mac-
rophages and Deauville score at interim PET may indicate 
that lymphomas with higher initial macrophage content 
are at higher probability of treatment resistance, or that 
persisting macrophages contribute to residual accumula-
tion of [18F]- FDG. On the other hand, one could also 
speculate that persisting macrophages stimulate metabolic 
activity of HRS cells.
We found that the presence of B- symptoms is an in-
dependent prognosticator in the multivariate analysis. B- 
symptoms are associated with a variety of other laboratory 
abnormalities and patient characteristics, in particular 
advanced- stage disease, and therefore have been often 
removed in multivariate analyses models, as in the IPS 
[35]. B- symptoms are due to the production of pro- 
inflammatory cytokines by the Hodgkin tumor tissue, in 
particular IL- 1, TNF- alpha, and IL- 6, which are detected 
at increased levels in peripheral blood [37]. We found 
that TARC levels are not predictive of outcome. On the 
other hand, cytokine models including IL- 6, sCD30 and 
TNFR1 levels was more predictive than the standard clini-
cal score [37]. It will be of great interest to explore whether 
in the multivariate analysis including CD68+ cell counts 
and interim PET, the cytokine score could beat clinical 
characteristics as B- symptoms.
Our study shows that histological (CD68 counts) and 
clinical characteristics at diagnosis provide prognostic 
 information already at treatment start, and not only 
 after 2 cycles of ABVD. Patients with low CD68+ cell counts 
and without B- symptoms may have a favorable outcome, 
despite a positive interim PET scan. On the other hand, 
patients with high CD68+ cell counts and B- symptoms are 
at high risk, and treatment results may be poor also in 
the presence of a negative interim PET. It remains to be 
determined whether this group could benefit from 
Figure 4. Progression- free survival according to interim positron emission tomography (PET) scan in patients according to CD68+ cell count and B- 
symptoms. PFS curves are shown for patients with CD68+ <5% and no B- Symptoms (A), CD68 > 5% or B- symptoms (B), and CD68% >5 and B- 
symptoms (C). The continuous line indicates patients with negative interim PET, the dashed line patients with a positive interim PET. The survival 
difference is significant in patients with both CD68 counts >5% and B- symptoms (P = 0.003), while there is a trend for significance in the group with 
either CD68 count>5% or B- symptoms (P = 0.06).
Table 4. Multivariate Cox analysis of progression- free survival of 79 
 patients with HL, treated with ABVD.
Variable
Hazard 
ratio 95% CI P*
PET Positive versus 
negative
7.5 2.3–24.7 0.001
CD68 >5% versus <5% 4.3 1.4–13.5 0.01
Stage IIB- IV versus I- IIA 0.8 0.2–3.3 0.8
B- symptoms Yes versus no 4.4 1.1–18.6 0.04
IPS score >2 versus 0–2 0.8 0.3–2.5 0.8
Significant P-values are shown in bold.
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intensified treatment strategies, as the BEACOPP regimen, 
or addition of new agents, as brentuximab vedotin, right 
from therapy start. In advanced HL, we are still in need 
of markers that are not only prognostic, but predictive 
and can help to tailor first- line therapeutic approaches.
In conclusion, the frequency of CD68+ macrophages 
at HL diagnosis remains a significant prognostic marker. 
Patients with a CD68 count >5% and B- symptoms are 
at high- risk for early progression. It is important to un-
derline that the numbers of this subgroup analyses are 
small and have therefore to be considered explorative. 
Technological improvements in the near future using the 
nanostring technology will probably render the evaluation 
of the tumor- associated macrophage count more robust 
and overcome some variability due to the use of different 
antibody clones (KP1 and PGM1), varying thresholds and 
inter- observer differences [38]. Moreover, validation of 
our data on a potential prognostic algorithm integrating 
information at diagnosis and response evaluation accord-
ing to interim PET- CT may provide the basis for in-
novative risk- adapted treatment protocols in HL.
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